JP2023542211A - 神経疾患を処置するための方法 - Google Patents

神経疾患を処置するための方法 Download PDF

Info

Publication number
JP2023542211A
JP2023542211A JP2023518391A JP2023518391A JP2023542211A JP 2023542211 A JP2023542211 A JP 2023542211A JP 2023518391 A JP2023518391 A JP 2023518391A JP 2023518391 A JP2023518391 A JP 2023518391A JP 2023542211 A JP2023542211 A JP 2023542211A
Authority
JP
Japan
Prior art keywords
disease
composition
disorder
nucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542211A5 (cg-RX-API-DMAC7.html
Inventor
アンナ トレチャコヴァ,
レスター スアレス,
アン ブラーイ,
マイケル エル. ロバーツ,
フィリップ モリエ,
Original Assignee
アスクレピオス バイオファーマシューティカル, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスクレピオス バイオファーマシューティカル, インコーポレイテッド filed Critical アスクレピオス バイオファーマシューティカル, インコーポレイテッド
Publication of JP2023542211A publication Critical patent/JP2023542211A/ja
Publication of JP2023542211A5 publication Critical patent/JP2023542211A5/ja
Priority to JP2026062800A priority Critical patent/JP2026099946A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13098—Cholesterol 24-hydroxylase (1.14.13.98)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023518391A 2020-09-21 2021-09-21 神経疾患を処置するための方法 Pending JP2023542211A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026062800A JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063080925P 2020-09-21 2020-09-21
US63/080,925 2020-09-21
US202063121152P 2020-12-03 2020-12-03
US63/121,152 2020-12-03
US202163139410P 2021-01-20 2021-01-20
US63/139,410 2021-01-20
US202163140440P 2021-01-22 2021-01-22
US63/140,440 2021-01-22
US202163180407P 2021-04-27 2021-04-27
US63/180,407 2021-04-27
PCT/US2021/071534 WO2022061378A2 (en) 2020-09-21 2021-09-21 Methods for treating neurological disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026062800A Division JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Publications (2)

Publication Number Publication Date
JP2023542211A true JP2023542211A (ja) 2023-10-05
JP2023542211A5 JP2023542211A5 (cg-RX-API-DMAC7.html) 2024-08-22

Family

ID=80776430

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023518391A Pending JP2023542211A (ja) 2020-09-21 2021-09-21 神経疾患を処置するための方法
JP2026062800A Pending JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026062800A Pending JP2026099946A (ja) 2020-09-21 2026-04-06 神経疾患を処置するための方法

Country Status (7)

Country Link
US (1) US20230365963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213891A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023542211A (cg-RX-API-DMAC7.html)
AU (1) AU2021344607A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193406A1 (cg-RX-API-DMAC7.html)
IL (1) IL301525A (cg-RX-API-DMAC7.html)
WO (1) WO2022061378A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
EP4423272A2 (en) * 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
AU2023211606A1 (en) * 2022-01-27 2024-07-11 AskBio Inc. Compositions for treating neurological disease
CN119451703A (zh) * 2022-04-25 2025-02-14 迈特勒公司 髓鞘病症的治疗
WO2024079317A1 (en) * 2022-10-14 2024-04-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies
WO2024149844A1 (en) * 2023-01-12 2024-07-18 Nantes Université Chemically-modified adeno-associated virus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034540A1 (en) * 2007-09-12 2011-02-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of the CYP46A1 Gene for the Treatment of Alzheimer's Disease
JP2013544236A (ja) * 2010-10-15 2013-12-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ハンチントン病の治療法におけるコレステロール−24−ヒドロラーゼのための発現ベクター
US20190298754A1 (en) * 2016-12-02 2019-10-03 Seoul National University R&Db Foundation Use of microrna-188-5p for treating alzheimer's disease
JP2019533439A (ja) * 2016-09-22 2019-11-21 ユニバーシティ オブ マサチューセッツ ハンチントン病のaav処置
US20200071699A1 (en) * 2018-08-31 2020-03-05 Ghassan S. Kassab Treatment of alzheimers disease with micro rna and ghrelin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288231A1 (en) * 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
WO2009149418A2 (en) 2008-06-06 2009-12-10 Asuragen, Inc. Novel compositions for the in vivo delivery of rnai agents
KR101367568B1 (ko) * 2011-05-31 2014-02-27 임우석 Abc 수송체 조절을 통한 퇴행성신경질환에서 이상단백질 조절
RU2014112958A (ru) 2011-09-21 2015-10-27 Йиссум Ресерч Девелопмент Компани оф де Хебрю Юниверсити оф Джерусалем Лтд. Наносистемы доставки для мирнк
ES2661236T3 (es) 2011-12-13 2018-03-28 Henry Ford Health System Procedimientos, sistemas y composiciones para administración de microARN derivado de células/a base de vesículas
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
WO2019177550A1 (en) 2018-03-10 2019-09-19 Koc Universitesi Therapeutic nanoparticles containing argonaute for microrna delivery and compositions and methods using same
WO2020089154A1 (en) * 2018-10-29 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034540A1 (en) * 2007-09-12 2011-02-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of the CYP46A1 Gene for the Treatment of Alzheimer's Disease
JP2013544236A (ja) * 2010-10-15 2013-12-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ハンチントン病の治療法におけるコレステロール−24−ヒドロラーゼのための発現ベクター
JP2019533439A (ja) * 2016-09-22 2019-11-21 ユニバーシティ オブ マサチューセッツ ハンチントン病のaav処置
US20190298754A1 (en) * 2016-12-02 2019-10-03 Seoul National University R&Db Foundation Use of microrna-188-5p for treating alzheimer's disease
US20200071699A1 (en) * 2018-08-31 2020-03-05 Ghassan S. Kassab Treatment of alzheimers disease with micro rna and ghrelin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
日本臨床, vol. 70, no. 8, JPN6025041449, 2012, pages 383 - 387, ISSN: 0005901449 *

Also Published As

Publication number Publication date
AU2021344607A1 (en) 2023-06-01
JP2026099946A (ja) 2026-06-18
WO2022061378A2 (en) 2022-03-24
WO2022061378A3 (en) 2022-04-28
EP4213891A4 (en) 2025-07-23
IL301525A (en) 2023-05-01
US20230365963A1 (en) 2023-11-16
CA3193406A1 (en) 2022-03-24
AU2021344607A9 (en) 2024-09-12
EP4213891A2 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
US20260048104A1 (en) Methods and compositions for treating metabolic imbalance in neurodegenerative disease
AU2021344607A9 (en) Methods for treating neurological disease
US20020091094A1 (en) Glutamic acid decarboxylase (GAD) based delivery system
AU2018261003A1 (en) Compositions and methods of treating Huntington's Disease
JP7717398B2 (ja) Sod1二重発現ベクターおよびその使用
KR20240099360A (ko) 핵산 구축물, 바이러스 벡터 및 바이러스 입자
JP2025166191A (ja) ハンチントン病を処置するための方法
CN119677545A (zh) 用于治疗神经系统疾病的组合物
WO2025213111A2 (en) Aav expression of mirna to suppress human apoe mrna
CN116723868A (zh) 治疗神经系统疾病的方法
TW202214864A (zh) 用於藉基因療法治療諸如阿茲海默症之Tau蛋白病變的病毒顆粒
EP4329823A1 (en) Gm3 synthase vectors and uses thereof
HK40100119A (en) Methods for treating neurological disease
US20250250566A1 (en) Gene silencing by recombinant aav-amirna in alexander disease
KR20250006358A (ko) 파킨슨병의 치료를 위한 방법 및 조성물
WO2024102961A1 (en) Synthetic nucleic acids including astrocyte-directed promoter constructs and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260706